iCAD (NASDAQ:ICAD) issued an update on its first quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $8.10 M-, compared to the consensus revenue estimate of $7.89 million.
Shares of NASDAQ:ICAD traded down $0.88 on Tuesday, reaching $17.57. The company’s stock had a trading volume of 209,895 shares, compared to its average volume of 197,411. The stock’s 50-day moving average is $18.70 and its two-hundred day moving average is $14.76. iCAD has a 52-week low of $8.32 and a 52-week high of $21.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.52 and a quick ratio of 2.30. The stock has a market capitalization of $437.81 million, a P/E ratio of -18.49 and a beta of 1.30.
iCAD (NASDAQ:ICAD) last announced its earnings results on Wednesday, April 28th. The technology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. iCAD had a negative net margin of 67.61% and a negative return on equity of 55.84%. Equities analysts forecast that iCAD will post -0.45 earnings per share for the current fiscal year.
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment.
Featured Article: How Investors Can Profit from Options Trading
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.